Takeda's dengue vaccine candidate shows promise : vimarsana.

Japanese pharma company Takeda on Friday announced that its dengue vaccine candidate, TAK-003, prevented 84 per cent of hospitalised dengue cases and 61 per cent of symptomatic cases.The 4.5-year-long phase-3 clinical trial, which included over ...

Related Keywords

Japan , United States , India , New Delhi , Delhi , Singapore , Japanese , America , Serina Fischer , European Union , World Health Organisation , South East Asia , Latin America , Northern European Conference , Travel Medicine , Eng Eong Ooi , General Manager ,